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Approximately one-third of the U.S. population has
nonalcoholic fatty liver disease (NAFLD), a condition
closely associated with insulin resistance and in-
creased risk of liver injury. Dysregulated mitochon-
drial metabolism is central in these disorders, but
the manner and degree of dysregulation are dis-
puted. This study tested whether humans with
NAFLD have abnormal in vivo hepatic mitochondrial
metabolism. Subjects with low (3.0%) and high
(17%) intrahepatic triglyceride (IHTG) were studied
using 2H and 13C tracers to evaluate systemic lipol-
ysis, hepatic glucose production, and mitochondrial
pathways (TCA cycle, anaplerosis, and ketogenesis).
Individuals with NAFLD had 50%higher rates of lipol-
ysis and 30% higher rates of gluconeogenesis. There
was a positive correlation between IHTG content and
both mitochondrial oxidative and anaplerotic fluxes.
These data indicate that mitochondrial oxidative
metabolism is 2-fold greater in those with NAFLD,
providing a potential link between IHTG content,
oxidative stress, and liver damage.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is associated with
obesity and insulin resistance and affects approximately one-
third of the U.S. population (Browning and Horton, 2004; Brown-
ing et al., 2004; Clark et al., 2002). Although NAFLD can remain
benign, up to 50% of affected individuals will develop an insid-
ious form of liver disease known as nonalcoholic steatohepatitis
(NASH) that can progress to cirrhosis and liver failure (Browning
et al., 2004; Neuschwander-Tetri and Caldwell, 2003). The path-
ogenesis and progression of NAFLD involve multiple pathologic
states that appear to be associated with elevated liver fat
(Day and James, 1998). However, the precise cellular and/or
metabolic events that accompany steatosis and threaten liver
function remain unclear.804 Cell Metabolism 14, 804–810, December 7, 2011 ª2011 ElsevierAccumulation of triglyceride (TG) is characteristic of most
insulin-resistant tissues (Muoio and Newgard, 2008; Savage
et al., 2007). The connection between lipid metabolism and
insulin resistance hinges not on TG accumulation, per se, but
on the pathologic catabolism of TG and generation of lipid-
derived signaling molecules which impair insulin action. This
process originates with the impaired (Savage et al., 2007) or
incomplete mitochondrial catabolism (Muoio and Newgard,
2008) of intracellular lipid in insulin-resistant skeletal muscle.
A similar limitation of mitochondrial fatty acid oxidation in liver
(Bickerton et al., 2008) would provide a plausible basis for the
development of NAFLD during insulin resistance (Savage et al.,
2007). However, NAFLD appears to result predominantly from
increased adipose lipolysis, de novo lipogenesis, and perhaps
saturated lipoprotein TG export (Choi and Ginsberg, 2011; Don-
nelly et al., 2005; Fabbrini et al., 2008), with sparse in vivo data to
address the role of mitochondrial metabolism in the pathogen-
esis or progression of NAFLD.
Mitochondrial metabolism is indispensible for liver function
(Kucejova et al., 2011). Mitochondrial b-oxidation is upregulated
10-fold to accommodate large differentials in lipid influx and
insulin action (McGarry and Foster, 1980) during fasting. Induc-
tion of lipid oxidation is required for the endergonic steps of
gluconeogenesis and ureagenesis, pathways that are partially
localized in liver mitochondria and constitutively upregulated
during insulin resistance. Thus, unlike skeletal muscle, the
insulin-resistant and fatty liver may activate oxidative metabo-
lism (Iozzo et al., 2010; Sanyal et al., 2001). Chronic activation
of mitochondria in the setting of lipid overload could predispose
the liver to oxidative stress and cellular damage, events thought
to drive the development of NASH (Browning and Horton, 2004).
In fact, defects in hepatic mitochondria or the function of oxida-
tive phosphorylation similar to skeletal muscle are typically
observed only during NASH or diabetes (Caldwell et al., 2009;
Cortez-Pinto et al., 1999; Pe´rez-Carreras et al., 2003; Szen-
droedi et al., 2009). Thus, mitochondrial metabolism almost
certainly plays a role in hepatic insulin resistance and NAFLD
(Wei et al., 2008), but the nature of this role is poorly understood.
The present study examined hepatic mitochondrial pathways
in humans with low or high liver fat. Liver fat was quantified
by MRS, and subjects were administered 2H and 13C tracers
to evaluate gluconeogenesis, hepatic TCA cycle activity,Inc.
Table 1. Clinical and Laboratory Characteristics of Human Subjects
Subject Characteristics Low IHTG (%6%) High IHTG (>6%) P Value
Intrahepatic TG (%) 3.0 ± 2.4 (0.0–6.0) 17.4 ± 2.8* (12.8–21.3) <0.001
Hispanic/African American 3/5 6/2
Age (years) 44 ± 6 (36–51) 50 ± 11 (30–67) 0.210
Body weight (kg) 105.6 ± 24.8 (83.4–148.6) 88.4 ± 17.4 (59.2–116.8) 0.131
Lean body weight (kg) 58.4 ± 7.0 (52.9–73.5) 48.9 ± 10.4 (30.5–66.9) 0.075
Body fat (%) 39.5 ± 11.6 (22.9–55.7) 45.4 ± 9.3 (32.5–63.5) 0.282
BMI (kg/m2) 36.0 ± 9.0 (25.1–50.6) 34.8 ± 5.8 (28.1–42.5) 0.754
AST (U/L) 42 ± 30 (14–102) 62 ± 46 (22–121) 0.329
ALT (U/L) 50 ± 40 (15–117) 75 ± 52 (28–166) 0.306
Plasma glucose (mg/dL) 92.5 ± 9.2 (75.3–107.5) 99.5 ± 19.7 (68.4–122.5) 0.377
HbA1c (%) 5.9 ± 0.2 (5.6–6.1) 6.0 ± 0.3 (5.7–6.4) 0.171
Plasma insulin (mU/L) 8 ± 5 (4–17) 14 ± 6 (6–25) 0.065
Hepatic insulin sensitivity index (102 umol1 min Kg mU1$L) 1.5 ± 0.29 (0.37–2.7) 0.62 ± 0.35 (0.25–0.83) 0.011
Insulin sensitivity index (104 min1 per mU/mL) 3.2 ± 1.6 (1.6–6.3) 2.1 ± 1.3 (0.9–3.1) 0.172
Fasting FFA (mmol/L) 0.58 ± 0.17 (0.29–0.86) 0.69 ± 0.11 (0.56–0.91) 0.155
Fasting plasma TG (mmol/L) 1.31 ± 0.73 (0.50–2.79) 1.22 ± 0.34 (0.71–1.70) 0.751
Values are represented as means ±SD with the range in parentheses. Each mean is an average of n = 8 human subjects. *p < 0.05 between subjects
with liver fat%6% and liver fat >6%.
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mitochondrial oxidative and anaplerotic TCA cycle activities
are elevated in subjects with NAFLD and correlate strongly
with liver fat content. We conclude that NAFLD develops in the
presence of chronic oxidative metabolism, a potential contrib-
uting factor to the progression from benign steatosis to NASH.
RESULTS
Subject Characteristics
Subjects had a wide range of IHTG content by 1H MRS
(0%–21%) and were thus separated equally into a low IHTG
and a high IHTG group (p < 0.001) (Table 1). The low IHTG group
was composed of subjects with IHTG%6% (3.0% ± 2.4%; n =
8), and the high IHTG group was composed of subjects with
IHTG >6% (17.4% ± 2.8%; n = 8). As expected from a previous
population study (Guerrero et al., 2009; Browning et al., 2004),
the low IHTG group consisted mostly of African Americans
(five out of eight), while the high IHTG group consisted of mostly
Hispanics (six out of eight), though the relatively low number of
subjects precluded an analysis based on ethnicities. High and
low IHTG groups were matched for age, body mass index, and
body fat content (Table 1). Plasma chemistries, including fasting
blood glucose and HbA1c, were not different between the
groups. However, plasma insulin concentration (p = 0.07) tended
to be higher, and hepatic insulin sensitivity (p = 0.01), but not
whole-body insulin sensitivity (p = 0.17), index was impaired in
the high IHTG group (Table 1). These data demonstrate that
the primary differences between the low and high IHTG groups
were IHTG content and hepatic insulin sensitivity.
Gluconeogenesis Is Elevated in Individuals
with High IHTG Content
Inasmuch as NAFLD is associated with insulin resistance, we
examined endogenous glucose production and gluconeogen-Cell Mesis following a standardized meal and overnight fast. Endoge-
nous glucose production tended to be higher in subjects
with high IHTG (p = 0.08; Figure 1A), and gluconeogenic flux
was elevated by 25% in subjects with high IHTG (p = 0.05;
Figure 1A). However, the contribution of glycogenolysis to
endogenous glucose production was similar (p = 0.39) between
the groups (Figure 1A). These data indicate that elevated IHTG
content is associated with the dysregulation of gluconeogen-
esis, a finding that is consistent with impaired insulin action in
liver.
Mitochondrial Anaplerosis Is Increased in Individuals
with Elevated IHTG
Anaplerosis is the nonoxidative flux of intermediates into the TCA
cycle. In the liver this pathway is dominated by the actions of
mitochondrial pyruvate carboxylase (Walter et al., 1966), which
catalyzes the conversion of pyruvate to oxaloacetate and,
combined with cataplerotic efflux through phosphoenolpyrvate
carboxykinase (PEPCK), is the first step of gluconeogenesis.
To assess hepatic anaplerosis, subjects were administered an
oral dose of [U-13C3]propionate, which is metabolized to glucose
after incorporation into the hepatic TCA cycle (Landau et al.,
1993). The relative rate of anaplerosis, flux of TCA cycle carbons
into gluconeogenesis, and TCA cycle turnover were detected by
the 13C spin coupling patterns in the 13C NMR spectrum of
plasma glucose (Browning et al., 2008; Jones et al., 2001).
Hepatic anaplerotic flux was increased by 50% in subjects
with high IHTG (p = 0.015; Figure 1B), indicating increased flux
through the combined pathways of mitochondrial PC and
PEPCK, and is consistent with the increased rate of gluconeo-
genesis observed in subjects with high IHTG. Pyruvate cycling,
which is a futile cycle linking anaplerotic flux to the regeneration
of pyruvate through pyruvate kinase or malic enzyme, was also
elevated by 55% in subjects with high IHTG (p = 0.015; Fig-
ure 1B). Together, these data indicate that the anabolicetabolism 14, 804–810, December 7, 2011 ª2011 Elsevier Inc. 805
Figure 1. Glucose and Mitochondrial Fat Metabolism in Human Subjects with Low or High IHTG Content
2H and 13C isotopomer analysis of plasma glucose and b-hydroxybutyrate by NMR and FFA by GC-MS was used to determine hepatic flux in overnight fasted
individuals. Shown are (A) endogenous glucose production and its contributions from gluconeogenesis and glycogenolysis in hexose units, (B) anaplerotic flux as
an estimate of pyruvate carboxylase and PEPCK flux and its contribution to pyruvate cycling and gluconeogenesis, (C) hepatic TCA cycle flux in acetyl-CoA units,
(D) apparent b-hydroxybutyrate turnover as an estimate of ketogenesis; (E) correlation between TCA cycle flux and anaplerosis; and (F) FFA turnover as an
estimate of systemic lipolysis. Data are presented as means ±SEM (n = 8) with significance declared at p% 0.05 and p% 0.1 considered a trend.
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viduals with high IHTG.
Mitochondrial Oxidative Metabolism Is Increased
in Liver of Subjects with Elevated IHTG
Lipid oxidation is the principal source of energy generation in
liver, and its dysregulation represents a potential metabolic link
between NAFLD, mediators of insulin resistance, and hepatocel-
lular damage. Subjects with NAFLD had an 2-fold induction in
oxidative flux through TCA cycle (p = 0.002; Figure 1C). Liver TG
content was positively correlated with hepatic TCA cycle flux (r =
0.71; p = 0.002), indicating that oxidative metabolism in themito-
chondrial TCA cycle is not impaired even at very high IHTG levels
in humans. However, ketone production assessed by tracer dilu-
tion of b-hydroxybutyrate was not different between subjects
with low and high IHTG (Figure 1D). These data indicate that
excess acetyl-CoA was selectively partitioned to oxidation in
the TCA cycle rather than ketogenesis, perhaps due to increased
energy requirements of the fatty liver. There was a strong corre-
lation between TCA cycle flux and PC/PEPCK (anaplerosis and
cataplerosis) (r = 0.87; p < 0.001; Figure 1E), consistent with
the induction of gluconeogenesis by fat oxidation (Chen et al.,
1999; Roden et al., 2000; Staehr et al., 2003), and also suggest-
ing that part of the increased energy demand/production of the
fatty liver is associated with increased gluconeogenesis.
FFA Delivery Is Increased in NAFLD
Since dysregulated fatty acid homeostasis contributes to the
pathophysiology of insulin-resistant liver, we evaluated systemic806 Cell Metabolism 14, 804–810, December 7, 2011 ª2011 Elsevierfree fatty acid (FFA) metabolism. Plasma FFA concentration was
insignificantly increased (Table 1), but systemic lipolysis as-
sessed by 13C FFA turnover (RaFFA) was 2-fold higher in
subjects with elevated IHTG content compared to subjects
with low IHTG (p = 0.035; Figure 1F). RaFFA was also closely
associated with b-hydroxybutyrate turnover (r = 0.58; p =
0.039). These findings agree with earlier reports (Fabbrini et al.,
2008) and are consistent with a role for increased FFA delivery
in the induction of hepatic mitochondrial oxidative metabolism
during NAFLD.
DISCUSSION
Hepatic steatosis occurs because of an imbalance between lipid
accrual (uptake, synthesis) and disposal (secretion, oxidation).
The contributions of dietary lipid intake, lipogenesis, lipolysis,
and lipoprotein secretion to the development of NAFLD have
all been studied in humans (Choi and Ginsberg, 2011; Diraison
et al., 2003; Donnelly et al., 2005; Fabbrini et al., 2008). Mito-
chondrial metabolism occupies the nexus connecting insulin
resistance, steatosis, oxidative stress, and the dysregulation of
metabolic pathways like gluconeogenesis (Muoio and Newgard,
2008; Savage et al., 2007), but its role in the pathogenesis
of NAFLD has not been systematically evaluated in humans.
We report that the pathophysiology of NAFLD is marked by
increased hepatic mitochondrial metabolism, as illustrated in
Figure 2. This conclusion is supported by a 2-fold increase in
hepatic TCA cycle flux in subjects with elevated IHTG content
and a strong correlation between TCA cycle flux and IHTGInc.
Figure 2. Hepatic Mitochondrial Metabolism Is Increased in Subjects with Nonalcoholic Fatty Liver Disease
Subjects with increased IHTG had elevated adipose lipolysis which contributed to increased lipid delivery to liver. Hepatic TCA cycle flux was increased,
indicating upregulatedmitochondrial respiration (at least via complex II) and suggesting increased flux of acetyl-CoA from b-oxidation. Mitochondrial anaplerosis
was also increased and provided substrate for the increased rate of gluconeogenesis observed in subjects with high IHTG. Pathways that are increased during
high IHTG are designated by [.
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pyruvate carboxylase flux [Walter et al., 1966]) was also in-
creased by roughly 50%, contributing to elevated rates of gluco-
neogenesis and partially accounting for the attendant increase in
hepatic energy demand in people with high IHTG. We conclude
that hepatic steatosis develops in the presence of elevated mito-
chondrial oxidative and anabolic metabolism in the liver.
Two principal hypotheses prevail regarding the function of
mitochondrial metabolism during insulin resistance and NAFLD.
First is the concept that impaired mitochondrial capacity results
in the pathologic formation of lipid metabolites which deactivate
the insulin signaling cascade through a PKC-dependent mecha-
nism (Samuel et al., 2004; Savage et al., 2007). This hypothesis is
compelling, because it addresses both the underlying etiology of
insulin resistance and the concurrent intracellular lipid accumu-
lation. Mitochondrial dysfunction has been reported in insulin-
resistant skeletal muscle as morphologic defects, decreased
mitochondrial content, respiration, ATP synthesis, and TCA
cycle turnover (Kelley et al., 2002; Petersen et al., 2004; Sparks
et al., 2005). In liver, several reports indicate defects in in vivo
ATP synthesis in individuals with NASH (Cortez-Pinto et al.,
1999) or diabetes (Szendroedi et al., 2009), but the majority of
evidence is indirect. Hepatic lipid overload by short-term high-
fat feeding (Samuel et al., 2004), lipid infusion (Lam et al.,
2002), or inhibition of fat oxidation (Zhang et al., 2007) results
in hepatic insulin resistance, while increasing mitochondrial fat
oxidation is sufficient to suppress liver PKC (Samuel et al.,Cell M2004) and improve insulin sensitivity. Certainly the data in the
present study support increased hepatic lipid burden, as indi-
cated by elevated lipolysis, but surprisingly, the data revealed
no indication of a mitochondrial insufficiency.
A second hypothesis holds that chronic lipid overload in the
liver of individuals with NAFLD induces mitochondrial oxidation,
resulting in oxidative stress and eventual damage to cellular
components including mitochondria, ushering in inflammation,
cell death, and the progression from benign steatosis to NASH
(Browning and Horton, 2004; Day and James, 1998; Diehl et al.,
2005; Pessayre and Fromenty, 2005). Indeed, individuals with
NASH have elevated circulating ketones (Sanyal et al., 2001),
and obese humans have a 2-fold increase in hepatic 11C-palmi-
tate oxidation by positron emission tomography (Iozzo et al.,
2010). We found that increased lipolytic rates were associated
with elevated b-hydroxybutyrate turnover, although no differ-
ences were detected between the low and high IHTG groups.
Thismight be related to the fact that wewere unable to determine
acetoacetate contribution to ketone turnover because of unex-
pectedly low enrichments and concentrations. Nonetheless,
elevated hepatic TCA cycle flux demonstrated thatmitochondrial
oxidative activity is increased in people with high liver fat.
Although histology was not characterized in these subjects,
elevated oxidative metabolism may be an important contributor
to the oxidative stress that attends the progression to NASH.
Inasmuch as mitochondrial TCA cycle activity is closely gov-
erned by energy demand, we interpret this finding to indicateetabolism 14, 804–810, December 7, 2011 ª2011 Elsevier Inc. 807
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distinct from lipid overload, per se, because it implies that
the downstream pathways requiring oxidative metabolism are
elevated in addition to the oversupply of oxidative substrate
(lipid). Congruent with this interpretation is an increase in mito-
chondrial anaplerosis with IHTG content (r = 0.53; p = 0.035)
leading to a 30% higher rate of gluconeogenesis in individuals
with elevated IHTG content. In this respect, lipid overload in-
duces constitutive activation of mitochondrial activity and gluco-
neogenesis, a pathway with substantial endergonic require-
ments and a phenomenon that is well known in humans (Chen
et al., 1999; Roden et al., 2000; Staehr et al., 2003). Nonetheless,
elevated gluconeogenesis is unlikely to be sufficient to account
for the 2-fold higher TCA cycle activity in individuals with NAFLD,
suggesting that other endergonic processes may also be in-
volved. In addition to activation of specific intermediary path-
ways during insulin resistance, ongoing liver damage during
NAFLD and concomitant hepatocellular regeneration may be
sufficient to increase the energy requirements of the liver, as
occurs in other forms of liver damage (Schofield et al., 1987).
Alternatively, mitochondria may simply be less efficient during
NAFLD, a possibility supported by mitochondrial damage (Cald-
well et al., 2009; Pessayre and Fromenty, 2005) and uncoupling
(Serviddio et al., 2008) in the liver of NASH patients. The cause of
mitochondrial damage has been proposed to be the result of
constitutive overactivation of oxidative metabolism during
NAFLD, a view substantiated by the current findings. The oxida-
tive stress associated with elevated hydride production in the
TCA cycle may be sufficient to damage the electron transport
chain during chronic steatosis, a condition functionally manifest
by impaired ATP synthesis in people with NASH (Cortez-Pinto
et al., 1999) or diabetes (Szendroedi et al., 2009). This would
result in a degenerative spiral whereby damaged electron trans-
port chain in turn requires elevated TCA cycle activity to produce
sufficient reducing equivalents for normal ATP and cellular
homeostasis.
In summary, the data provide direct evidence of elevated
in vivo hepatic mitochondrial metabolism in human subjects
with NAFLD. The strong association between IHTG content
and hepatic oxidative and anaplerotic TCA cycle activity demon-
strates the induction ofmitochondrial fatmetabolism in response
to lipid overload during NAFLD. Simultaneous induction of path-
ways of lipid accretion, oxidation, and gluconeogenesis heralds
oxidative stress, loss of glycemic control, and potential damage
to the liver during chronic hepatic steatosis.
EXPERIMENTAL PROCEDURES
Human Subjects
Sixteen subjects were recruited from health fairs and physician referrals.
The inclusion criteria were African American or Hispanic subjects overweight
or obese with elevated liver enzymes (ALT >30, AST >30) and/or charac-
teristics of the metabolic syndrome (Grundy et al., 2004), including elevated
waist circumference (>102 cm men, 88 cm in women), fasting glucose
(R110 mg/dL), blood pressure (>130/>85), elevated TG (R150 mg/dL, low
HDLc (<40mg/dL for men, <50 for women). Subjects were nondiabetic (fasting
glucose <125 mg/dl and/or HbA1c <6.5), aged 20–67 years, with stable body
weight and maintenance of preenrollment physical activity. The intensive
nature of the tracer studies precluded larger population studies. To ensure
a wide range of IHTG content, Hispanics (n = 9; 2 males and 7 females) and
African Americans (n = 7; 2males and 5 females) were recruited because these808 Cell Metabolism 14, 804–810, December 7, 2011 ª2011 Elseviertwo ethnicities have disparate predispositions for NAFLD (Browning et al.,
2004). Each subject participated in two metabolic tests. The first admission
included an assessment of insulin sensitivity using an insulin-modified intrave-
nous glucose tolerance test (IVGTT) (Boston et al., 2003) and stable isotope
administration to profile hepatic glucose and mitochondrial metabolism by
NMR (Browning et al., 2008; Jones et al., 2001). During the second admission,
liver TG content was assessed by 1H MRS and whole-body fatty acid flux via
stable isotope infusion and GC/MS (Barrows and Parks, 2006). All subjects
gave written informed consent prior to inclusion in this study, which was
approved by the Institutional Research Board (IRB) at UT Southwestern
Medical Center (approval #062007-025).
Study Design and Procedures
Before admission to the Clinical and Translational Research Center (CTRC),
subjects consumed weight-maintaining diets formulated by comparison to
the previous 3 day dietary record. This diet was prepared by the CTRC meta-
bolic kitchen and delivered to the subjects for consumption on an outpatient
basis for 3 days before admission #1 and for 7 days before admission #2.
Once admitted to the CTRC, identical evening meals were provided the
evening before admissions #1 and #2. The energy content of the meal repre-
sented 40% of the subject’s daily energy needs, and the composition of these
meals averaged (mean ±SD) 790.4 ± 118.7 kcal, 15.8 ± 8.2 g protein, 90.1 ±
22.7 g carbohydrate, 4.22 ± 2.11 g fiber, and 83.3 ± 11.9 mg cholesterol.
Admission #1: Measurements of Insulin Sensitivity
and Hepatic Metabolism
As shown in Figure S1, available with this article online, admission #1 included
an overnight CTRC stay with the IVGTT, DEXA (Hologic DiscoveryW, QDR
series), and administration of oral [U-13C]propionate and deuterated water
and intravenous infusion of [3,4-13C2]glucose, [1,2-
13C2]b-hydroxybutyrate,
[3,4-13C2]acetoacetate stable isotopes to profile hepatic glucose and mito-
chondrial metabolism as previously reported (Browning et al., 2008; Satapati
et al., 2008) and detailed in the Supplemental Information. The IVGTT was per-
formed, and glucose and insulin responses were analyzed using the minimal
model technique and the MINMOD Millenium software (Boston et al., 2003).
Hepatic insulin sensitivity index was calculated as 100/(EGP 3 fasting insulin)
(DeFronzo, 1988).
Admission #2: Measurement of IHTG and Fatty Acid Turnover
Within 2 weeks of admission #1, the subject underwent a 1H-MRS to assess
IHTG as previously described and detailed in the Supplemental Information.
Immediately following 1H-MRS, subjects were admitted to the CTRC for
measurement of the rate of appearance of FFA (RaFFA). After consump-
tion of the evening meal, a constant infusion (0000–1200 the next day) of
[13C4]palmitate (7 mg/kg/min bound to albumin) was performed as described
previously (Barrows and Parks, 2006) and detailed in the Supplemental
Information.
Metabolic Flux in the Liver
Ketones were isolated from 10 ml of plasma, and apparent ketone turnover
was assessed from their 13C tracer enrichment indicated by 13C NMR as we
previously described (Satapati et al., 2008) and detailed in the Supplemental
Information. Deuterium enrichment of glucose was used to determine frac-
tional gluconeogenesis as originally described by Landau (Landau et al.,
1995) and adapted for 2H NMR analysis (Jones et al., 2001). Carbon-13 iso-
topomers of glucose imparted by the oral [U-13C]propionate (Landau et al.,
1993) were evaluated by 13C NMR spectroscopy (Browning et al., 2008; Jones
et al., 2001) and used to determine fractional TCA cycle and anaplerotic
fluxes (Magnusson et al., 1991) as detailed in the Supplemental Information.
Fractional fluxes were converted to absolute fluxes by normalization with
endogenous glucose production (EGP) determined by [3,4-13C2]glucose turn-
over (Browning et al., 2008; Jones et al., 2001).
Metabolites and Hormone Measurements
Blood samples were collected in tubes containing sodium fluoride for plasma
glucose and tubes containing EDTA for plasma insulin and FFA. Plasma from
the EDTA tubes was separated immediately by centrifugation at 2,850 RPM for
10 min at 5C and stored at 20C. For measurement of plasma metaboliteInc.
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and FFA (WAKO, #999-34691, #991-34891); insulin was measured by ELISA
(Millipore, Billerica, MA, #EZHI-14L).
Reagents and Materials
[3,4-13C2]glucose (98%) was purchased from Omicron Biochemicals (South
Bend, IN). [1,2- 13C]sodium b-hydroxybutyrate (98%), [3,4-13C2]acetoacetate,
and [13C4]palmitate were purchased from Isotec (St. Louis, MO); [U-
13C]
propionate and deuterium oxide (99%) were purchased from Cambridge
Isotopes (Andover, MA). Other common chemicals were obtained from Sigma
(St. Louis, MO).
Statistical Analysis
Differences between groups were determined using unpaired, two-tailed
t tests. Data are presented as means ±SD. Spearman correlation analysis
was used to determine the correlation between two variables of interest.
Statistical significance was taken as p % 0.05, and a p % 0.1 was reported
as a trend.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Figure S1, and Supplemental References and can be found with this article
online at doi:10.1016/j.cmet.2011.11.004.
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